Acute Lymphoblastic Leukemia/Acute Myeloid Leukemia

These findings reinforce that matching therapy intensity and type to genetic and treatment-history profile is likely to be the next lever for improving outcomes.

Emily Curran, MD, University of Cincinnati, calls for decentralized trials and stronger community-academic ties to widen ALL patient access.

Karilyn Larkin, MD, traces her equity focus to her medically underserved hometown, urging new diagnostics, trial design, and honest patient talks to close AML gaps.

Bhavana Bhatnagar, DO, who moved from academic to community oncology, shares why stronger academic-community partnerships are essential for patient care.

Phase 1 BALLI-01 data showed UCART22 induced remissions with limited severe CRS/ICANS in relapsed/refractory B-cell ALL, supporting phase 2.

FDA approves Orca-T precision Treg cell therapy for matched donor transplants, cutting chronic GVHD risk and boosting survival in blood cancers.

Emily K. Curran, MD, discusses how newer ALL therapies are reshaping treatment decisions and minimal residual disease monitoring for older adults.

Independent investigations found that venetoclax-based combination regimens achieved high response and strong MRD negativity in newly diagnosed leukemias.

Phase 1 BALLI-01 trial results showed promising UCART22 activity in R/R B-cell ALL, with higher remission rates after a manufacturing change.

Baseline QOL is an independent prognostic factor for survival in AML, with global QOL carrying the largest HR, according to Fabio Efficace, PhD, MSc.

Amid the genomic revolution reshaping AML treatment, Karilyn Larkin, MD, speaks to why every patient deserves a personalized road to cure.

Emily Curran, MD, explains how newer immunotherapies are reshaping B-cell ALL treatment for older adults and why 10-year-old assumptions no longer apply.

New review details biologic, psychosocial, and treatment barriers shaping outcomes in AYA acute lymphoblastic leukemia (ALL).

Bhavana (Tina) Bhatnagar, DO, explains how age, comorbidities, fertility, and individual goals drive personalized treatment decisions in ALL and AML.

Karilyn Larkin, MD, weighs in on how decitabine/cedazuridine/venetoclax could transform the AML treatment experience—and the new responsibilities it places on patients.

Taiho submitted the supplemental new drug application in April 2025 for decitabine/cedazuridine and venetoclax, and the FDA accepted it for review in July 2025.

Pediatric Sequential Organ Failure Assessment may better predict death in ALL and sepsis, supporting earlier ICU intervention.

Once-feared disease markers are losing their sting as targeted therapies reshape the landscape of ALL, Emily K. Curran, MD, told AJMC.

A case study shows positive outcomes following allogeneic stem cell transplantation in a patient with highly refractory MM and therapy-related MDS/AML.

A faster, cheaper alternative to karyotyping, DNA index testing shows near-perfect accuracy for detecting high hyperdiploidy in pediatric patients with leukemia.

A new review explains how new therapies and technologies are guiding the treatment of acute myeloid leukemia (AML).

A comprehensive approach is necessary for navigating the highly heterogeneous nature of leukemia across different age populations, explains Tina Bhatnagar, DO.

Posttransplant gilteritinib maintenance therapy may boost survival and reduce relapse in relapsed FLT3-mutated acute myeloid leukemia (AML), but larger trials are still needed.

A new approach to posttransplant prophylaxis for graft vs host disease promises to increase access to the procedure to patients from minority groups with blood cancers. Investigators are now studying a lower dose of the treatment to limit toxicity.

Racial and ethnic disparities in outcomes persist in acute myeloid leukemia, but such disparities may not be tied to the use of tyrosine kinase inhibitors, according to a new report.